Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns “Buy” Rating from HC Wainwright

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $70.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 32.30% from the company’s previous close. HC Wainwright also issued […]

Leave a Reply

Your email address will not be published.

Previous post Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)
Next post Citigroup Reaffirms Neutral Rating for Getty Images (NYSE:GETY)